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Host proteinsBiomarkers for active tuberculosis (TB) are urgently needed to improve rapid TB diagnosis. The objective of
this study was to identify serum protein expression changes associated with TB but not latentMycobacterium
tuberculosis infection (LTBI), uninfected states, or respiratory diseases other than TB (ORD). Serum samples
from 209 HIV uninfected (HIV−) and co-infected (HIV+) individuals were studied. In the discovery phase
samples were analyzed via liquid chromatography and mass spectrometry, and in the veriﬁcation phase biolog-
ically independent samples were analyzed via a multiplex multiple reaction monitoring mass spectrometry
(MRM-MS) assay. Compared to LTBI and ORD, host proteins were signiﬁcantly differentially expressed in TB,
and involved in the immune response, tissue repair, and lipidmetabolism. Biomarker panels whose composition
differed according to HIV status, and consisted of 8 host proteins in HIV− individuals (CD14, SEPP1, SELL, TNXB,
LUM, PEPD, QSOX1, COMP, APOC1), or 10 host proteins in HIV+ individuals (CD14, SEPP1, PGLYRP2, PFN1, VASN,
CPN2, TAGLN2, IGFBP6), respectively, distinguished TB from ORDwith excellent accuracy (AUC= 0.96 for HIV−
TB, 0.95 for HIV+ TB). These results warrant validation in larger studies but provide promise that host protein
biomarkers could be the basis for a rapid, blood-based test for TB.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Accurate biomarkers for active tuberculosis (TB) are urgently need-
ed for the development of additional rapid diagnostic tests (Rylance
et al., 2010). Approximately a third of the world's population is infected
with Mycobacterium tuberculosis (Mtb) (World Health Organization,
2014). While about 90% of infected individuals remain asymptomatic,
in a state of latent Mtb infection (LTBI), approximately 10% develop TB
over their lifetime. This risk is about 20-40 times higher in HIV-
infected (HIV+) and otherwise immunocompromised individualsedicine, Division of Infectious
Rm. 115, 1300 Morris Park Ave,
J.M. Achkar),
. This is an open access article under(World Health Organization, 2011). In 2013, almost 9 million new TB
cases were diagnosed worldwide with almost one million TB-
associated deaths among HIV uninfected (HIV−) and ~0.43 million
among HIV+ individuals (World Health Organization, 2014). Corner-
stones of TB control are prevention and reduction of transmission,
both of which require timely TB diagnosis and treatment initiation
(World Health Organization, 2011). This need is especially high for rel-
atively early disease stages as these are the most challenging to diag-
nose. The current tests depend on the detection of Mtb, and require
specimens from the site of disease, typically sputum, which is not al-
ways readily obtainable and not helpful for the diagnosis of
extrapulmonary TB. Sputum microscopy and culture are further ham-
pered, respectively, by a lack of sensitivity or incubation times over
weeks (Pai et al., 2009). More recently, novel nucleic-acid based ampli-
ﬁcation methods have provided an alternative rapid method for the
detection of Mtb (Boehme et al., 2010, 2011), albeit at the need of a
sample containing a certain quantity of Mtb.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the discovery of biomarkers, and the development of additional diag-
nostics that do not require samples from the site of disease and that
are not based on the detection of Mtb. Mass spectrometry (MS) allows
rapid quantitative assessment of various analytes in clinical laborato-
ries, and portable MS technology is becoming more available (Wiley
et al., 2013; Hendricks et al., 2014; Creamer et al., 2014). Furthermore,
the technological base exists to develop and deploy multi-analyte
tests using multiple reaction monitoring MS (MRM-MS) (Hunter and
Paramithiotis, 2010), and immunoassays for the detection and quantiﬁ-
cation of speciﬁc proteins can be easily developed for settings where
fewer resources are available. Tests based on host protein panels have
already demonstrated diagnostic capability and prediction of disease
severity in conditions such as dengue fever and ovarian, endometrial
and lung cancers (Farias-Eisner et al., 2010; Li et al., 2013; Nosov et al.,
2009; Oikonomopoulou et al., 2008; Villar-Centeno et al., 2008). The
overall objective of this study was the identiﬁcation of protein expres-
sion patterns that are associated with TB but not with Mtb uninfected
states, LTBI, or respiratory diseases other than TB (ORD). Such bio-
markers might ultimately also be able to serve as surrogates for antitu-
berculous treatment response. In this study we focussed on subjects
living in the US as these are often diagnosed at earlier disease stages
than individuals living in more resource-limited settings (Achkar et al.,
2010), such asmany regions in Sub-Saharan Africa and Asia, wheremy-
cobacterial cultures are not always available and TB is typically not diag-
nosed until it is sputum smear-positive and highly transmissible (Reid
and Shah, 2009; Steingart et al., 2007). Due to the known impact of
HIV co-infection on the pathogenesis and clinical presentation of TB
(reviewed in (Achkar and Jenny-Avital, 2011)), we hypothesized thatFig. 1. Study design outline. An initial set of HIV-samples was used to identify proteins diff
M. tuberculosis infection). (A). The expression of a selected subset of 87 proteins was conﬁrme
the veriﬁcation analysis if their HIV status remained unidentiﬁed (N= 11) or if there were tec
in sample groups stratiﬁed by HIV status (C) as well as the ability of the biomarker candidates a
classiﬁcation of TB versus other respiratory diseaseswas established via nested cross-validation
active tuberculosis, LTBI = latentM. tuberculosis infection, NI = non-infected, ORD = other rethe host response in TB will differ according to HIV status. In this work
we show that TB leads to changes in blood protein expression, and dem-
onstrate that modestly sized panels of protein biomarkers that differed
according toHIV statuswere able to accurately distinguish TB fromLTBI,
and ORD.
2. Methods
2.1. Study Design and Subjects
Subjectswere categorized byHIV status and compared in a case con-
trol design with biologically independent sample sets in the discovery
and the veriﬁcation phase (Fig. 1). Sample sizewas determined by avail-
ability of serum samples. Subjects were enrolled at 4 public hospitals in
New York City from 2007–2011. They included symptomatic patients
suspected of having TB as well as asymptomatic controls (Table 1).
Symptomatic subjects were consecutively enrolled and represented
the spectrum of respiratory diseases that would undergo TB diagnostic
testing in the clinical setting. Inclusion criteria: 1) symptomatic subjects:
age ≥21 yrs old, and clinical suspicion with diagnostic work-up for TB;
2) asymptomatic controls: age ≥21 yrs old, with tuberculin skin-test
(TST) and/or interferon gamma release assay (IGRA) for routine occupa-
tional screening with normal chest X-ray in TST+ and/or IGRA+
subjects. Exclusion criteria: unknownHIV status at the time of data anal-
ysis, or technical sample issues (Fig. 1); antituberculous treatment for
more than 7 days, or history of TB or TB treatment within 1 year prior
to enrollment. Of note, none of the TB patients in the discovery phase
had received any prior treatment, and TB patients in the veriﬁcation
phase had received a median of 2 days (range 0–7 days) oferentially expressed in TB compared to controls (M. tuberculosis uninfected and latent
d using an independent set of HIV− and HIV+ samples (B). Samples were excluded from
hnical issues (N = 13). The remaining samples were used to verify the protein expression
nd their combinations to discriminate between TB and other respiratory diseases (D). The
using the classiﬁcation phase sample data split at random into 5 test and training sets. TB=
spiratory diseases.
Table 1
Characteristics of subjects included in discovery and veriﬁcation phase analysis.
Discovery phase Veriﬁcation phase
TB Controls TB ORDa Controls p
(n= 19) (n= 20) (n= 28) (n= 45) (n= 73) (TB vs ORD)
Age, mean (±SD) 42 (±15) 42 (±10) 40 (±13) 46 (±13) 44 (±12) .001f
Male (%) 13 (68) 7 (35) 21 (75) 35 (78) 38 (52) .78g
Race (%)
Asian 7 (41) 5 (25) 4 (14) 4 (10) 11 (15) .28g
Black 3 (18) 0 11 (39) 13 (31) 25 (35)
Caucasian 1 (6) 12 (60) 1 (4) 8 (19) 13 (18)
Hispanic 6 (35) 3 (15) 12 (43) 17 (40) 23 (32)
Foreign-bornb (%) 14 (74) 11 (55) 20 (71) 16 (36) 41 (56) .004g
BCG vaccinated (%) 14 (74) 9 (45) 20 (71) 15 (33) 39 (53) .004g
TST+c (%) NA 10 (50) NA NA 47 (64)
HIV+ (%) 0 0 10 (36) 26 (58) 39 (53) .07g
HAART (%) NA NA 2 (20) 15 (58) 33 (85) .15g
CD4 if HIV+, median (range) NA NA 145 (20–483) 129 (4–1070) 511 (11–1260) .84h
Symptom durationd, median weeks (range) 4 (0–52) NA 4 (0–52) 2 (0–24) NA b .001h
AFB+e (%) 8 (42) NA 10 (37) 5 (12) NA
M.tb culture+ (%)i 14 (74) NA 23 (85) 0 NA
TB location (%)
Pulmonary 16 (84) NA 17 (61) NA NA
Pulmonary & extrapulmonary 19 (16) NA 22 (18) NA NA
Extrapulmonary 0 NA 6 (21) NA NA
a ORD: other respiratory diseases than TB including community acquiredpneumonia (n=24), bronchitis (n=8), non-tuberculous lungdiseases (n=5; 4M. avium complex, 1M. kansasii),
and other diseases such as Pneumocystis jiroveci pneumonia, lung abscess and lung cancer (n = 8).
b Countries of origin for foreign-born individuals includedAfrican, Asian, South andMiddle American countries, aswell as theCaribbean Islandswithout Puerto Rico. Of note proportions
for foreign-born and race overlap.
c TST: tuberculin skin-test.
d Self-reported TB-associated symptoms such as cough, fever, night sweats and weight loss.
e AFB: sputum smears for acid-fast bacilli, considered positive if at least one of initial three smears was positive.
f t test.
g Chi-square test.
h Mann–Whitney U test.
i Culture-negative TBwas deﬁned as the initial 3 sputumsmears negative for acid fast bacilli andM. tuberculosis in cultures. Diagnosiswas conﬁrmed by a positive culture or nucleic acid
ampliﬁcation assay forM. tuberculosis in another specimen than the initial 3 sputa (e.g. bronchoalveolar lavage or lymph node biopsy in 3/19 (16%) in the discovery and 3/28 (11%) in the
veriﬁcation phase, by histology in 1/19 (5%) in the discovery phase, and by clinical and radiologic response in 1/19 (5%) subjects in the discovery and 2/28 (7%) in the veriﬁcation phase).
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ﬁrmed by either a positive culture for Mtb on one of the initial 3 sputum
samples, or in culture-negative cases (deﬁned as the initial 3 sputum
samples negative for AFB onmicroscopy and negative for Mtb bymyco-
bacterial culture) by positive culture and/or nucleic acid ampliﬁcation
assay and/or histology in another sample other than the initial 3
sputa, and/or by clinical response on antituberculous therapy (footnote
Table 1). Cases diagnosed as culture-negative TB typically had TB risk
factors, extensive diagnostic work-up to exclude other bacterial, fungal
or parasitic diseases, and were unresponsive to empiric antibacterial
treatment. The diagnosis of culture-negative TB was based on the
criteria of the American Thoracic Society and the Centers for Disease
Control and Prevention (American Thoracic Society, 2000; Blumberg
et al., 2003). This included chest-CT ﬁndings such as milliary or nodular
lung abnormalities consistent with TB. All of our culture-negative TB
cases were reported to the New York City Department of Health
(DOH), and the distribution of our TB cases was representative of that
reported by the DOH (New York City Department of Health and
Mental Hygiene, 2013). 2) Symptomatic controls consisted of patients
with signs and symptoms of TB who were ultimately diagnosed with
an ORD based on diagnostic work-up and as per physicians discharge
note (footnote Table 1). 3) Asymptomatic controls without abnormali-
ties on chest X-ray were categorized by TST results (Table 1). Due to
the CDC recommendation for LTBI screening with either TST or IGRA
(Mazurek et al., 2010), and the high costs of IGRAs, all of our controls
had TST results but only some had IGRA results available. Thus, TST+
subjects were classiﬁed as possible LTBI. Of note, 9/10 TST+ subjects
in our discovery phase also had a positive IGRA results available while
most subjects in our veriﬁcation phase had no IGRA test. Ethics state-
ment: Approval for human subjects' research was obtained from theInternal Review Boards at the New York University School of Medicine,
NY, NY, and the Albert Einstein College of Medicine, Bronx, NY. All sub-
jects provided written informed consent prior to enrolment.
2.2. Sample Processing
Subjects were bled at the time of enrolment, and serum aliquots
were stored at−80 °C until testing. Sample processing, liquid chroma-
tographyMS (LC–MS) andmultiplexMRM-MSwere performed by indi-
viduals blinded to the classiﬁcation and diagnosis of subjects. Samples
were grouped into blocks containing each of the disease groups. The
order of the samples within each block was randomized. Samples
were depleted of abundant proteins using an HSA/IgG column (Agilent
Technologie, Mississauga, ON) in tandem with an IgY14 and Supermix
(Sigma, Oakville, Ont) column and the ﬂow through digested with
trypsin (Promega, Madison, WI) at a trypsin to protein ratio of 1:10.
The digested samples were freeze-dried, resolubilized, and treated
with TCEP (tris(2-carboxyethyl)phosphine) to reduce disulﬁde bonds.
Samples were desalted by solid phase extraction using a 3 M Empore
C18 desalting plate and distributed into 96-well plates and vacuum
evaporated. Peptides were stored at−20 °C until use.
2.3. Tandem Mass Spectrometry Analysis
Samples were resuspended in 92.5/7.5 water/ACN + 0.2% formic
acid and analyzed by LC–MS (nanoAcquity pump HPLC and Q-TOF
mass spectrometer, Waters, Mississauga, Ont). Peptide separation was
achieved using a Waters nanoAcquity Symmetry UPLC Trap column
(180 μm × 20 mm, 5 μm particle size) and a Waters nanoAcquity
UPLC BEH300 analytical column (150 μm × 100 mm, 1.7 μm particle
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formic acid in acetonitrile. For each sample approximately 2.5 μg was
loaded onto the trap column for 4 min at a ﬂow rate of 6 μL/min.
Peptides were separated using a linear gradient (92.5% A to 75% A) at
0.6 μL/min for 57 min. MS spectra were acquired from 400–1600 Da.
Components were detected and matched across all samples using
the Elucidator software version 3.3.0.1.SP4.25 (Rosetta Biosoftware,
Seattle, WA) and compared for relative peak intensity. All intensity
values were log (base e) transformed, and after transformation values
b0 were replaced by 0. Intensity data was normalized to account for
small differences in protein concentration between samples. A subset
of the samples was used to create a reference sample against which all
samples were then normalized. The normalization factors were chosen
so that themedian of log ratios between each sample and the reference
sample over all the peptides was adjusted to zero. For batch-effect cor-
rection, a one-way ANOVA model Iij = M + Di + εij (I: intensity, M:
overall interception, and D: batch–factor) was solved and parameters
Di (i = 1,2) under the constraint of Σi = 12 (Ni*Di) = 0 were obtained;
the Di's were then subtracted from the normalized intensities to form
the ‘batch-effect corrected’ intensities. Intensities below a threshold
(IT; IT = 30) were transformed to avoid spurious large fold changes:
intensities in the range of (0, IT) were linearly mapped to the range of
(IT/2, IT). ANOVA analysis was then applied to identify differentially
expressed peptides. ANOVAmodel: Iij =M+Ci + εij where I is peptide
intensity, M is overall average intensity, C is ‘clinical group’ factor, and ε
random error (Keeping, 1995; Montgomery, 2001). False detection rate
and q-value were calculated based on the p-values obtained from the
ANOVA using Storey's method to make multiple testing adjustments
(implemented in MATLAB) (Storey, 2002). ‘Post-hoc’ contrast analyses
were conducted using Tukey's hsd method to calculate p-values for
each pair wise comparison (Hochberg and Tamhane, 2008). Protein
identiﬁcation was done by analysis of tandem mass spectrometry
(LC–MS/MS). Differentially expressed peptides were targeted for se-
quencing, and the resulting fragmentation patterns were matched to
the corresponding sequences found in a Human protein database
downloaded on20120531 fromUniprot, forwhich only reviewed entries
were kept, usingMascot software version 2.2.06 (Matrix Science, Boston,
MA). The following parameters were used for the searches: enzyme =
trypsin, allowed missed cleavages = 2, peptide tolerance = 20 ppm,
MS/MS tolerance = 0.4 Da, variable modiﬁcations = Deamination (N),
Oxidation (M). A decoy reverse database was used to evaluate false pos-
itive error rate. Peptide/Protein Teller helped derive the simplest list of
proteins to explain observed peptides, at a FDR calculated to be 6.3%. A
protein level analysis was then applied by introducing a ‘peptide factor’
in the ANOVA used above: Iijk = M + Ci + Pj + εijk where I is protein
intensity, M overall constant, C ‘clinical group’, and P peptide factor.
The number of the levels for P is protein-dependent, equal to the number
of peptides for the protein. Proteins were considered to be differentially
expressed if they met the following thresholds: p- and q-values b0.05
and differential intensity (DI) N1.1-fold change.
2.4. Multiple Reaction Monitoring Mass Spectrometry
Two-hundred-forty-four (244) peptides representing 87 host pro-
teins and 2 Mtb proteins were selected for the MRM-MS assay and
were synthesized (JPT Peptide Technologies, Berlin, Germany). Synthe-
sized peptides were resolubilized in 25/75 water/DMSO (v/v), pooled
and diluted with water + 0.2% formic acid to a concentration of
200 ng/mL. This peptide mix was used to develop the MRM-MS assay
on a NanoAcquity pump (Waters) coupled to a QTRAP 5500mass spec-
trometer (AB Sciex). Peptide separation was achieved using a BioBasic
C18 column (Thermo) (320 μm× 150mm, 5 μmparticle size). Gradient
timewas 30min and the ﬂow rate was 10 μL/min. The optimal 2 transi-
tions (combination of peptide precursor and fragment ion mass-to-
charge ratio that are monitored by the mass spectrometer) per peptide
were determined using selected reaction monitoring (SRM)-triggeredMS/MS on a QTRAP 5500 instrument (AB Sciex). The MRM-MS/MS
method was developed by calculating, for each peptide, the precursor
mass of the doubly and triply charged peptide ions and theﬁrst and sec-
ond y fragment ionwith anm/z greater than [m/z (precursor)+ 20Da].
If these calculated transitions were observed during the MRM-MS scan,
the instrument switched automatically to MS/MS mode and acquired a
full MS/MS spectrumof the precursor peptide ion. The twomost intense
fragment ions (b or y fragment ions only) in the MS/MS spectrum and
its elution time were determined for each acquired peptide. After, the
collision energy (CE) was optimized for each of the chosen transitions.
The developed MRM-MS assay was then applied for the analysis of the
study samples. A detailed description of the ﬁnal MRM-MS assay can
also be found at http://www.peptideatlas.org/passel/.
Expression analysis of MRM-MS data acquired from the veriﬁcation
samples was performed using R version 2.14.0, platform x86_64-pc-
mingw32/x64 (64-bit). The calculation of q-values was done using
function “qvalue” from Storey's package “qvalue” version 1.24.0
(Storey, 2002). An intensity threshold (IT) below which the measure
is deemed less reliable was determined empirically and set to 10,000
pre-normalization. A detection rate (DR) was deﬁned as the proportion
of samples within a group with a raw intensity value greater or equal
to the IT. Transitions with DR below 50% for one of the two groups
being compared were excluded from expression analysis. Differential
intensity (DI) ratios were calculated in pair wise comparisons for each
transition as the ratio of the median normalized intensities of each
group. Prior to calculating the DI ratios, all intensity values that were
below IT in the raw data prior to normalization were replaced by the
half-IT value. Student's t-test was applied for the expression analysis.
Protein-level statistics were also computed by linearly combining the
transitions of a given protein into a single variable and then applying a
t-test.
2.5. Network Analysis
Data were analyzed using Ingenuity Pathway Analysis (IPA;
Ingenuity® Systems, Redwood City, CA). Differential expression results
(DI b 1.1, p b 0.05, q b 0.05) were analyzed independently for HIV− and
HIV+ backgrounds. Proteins from the dataset that were associated with
biological functions and/or diseases in the Ingenuity Knowledge Base
were considered for the analysis. Right‐tailed Fisher's exact test was
used to calculate a p‐value determining the probability that each biolog-
ical function and/or disease assigned to that data set is due to chance
alone.
2.6. Panel Selection and Receiver Operating Characteristics
The area under the curve (AUC) was the result of a nested cross-
validation procedure that used stratiﬁed sampling to split the data at
random into ﬁve test sets, each with a proportion of TB to ORD samples
as close as possible to that of the full data set. For each test set, the
remaining four ﬁfths of the data were deﬁned to be that test set's corre-
sponding training set. To facilitate the selection of panels of interest, the
following procedure was carried out for all possible panels with up to
four proteins out of all the candidate biomarkers. Each training set
was again split at random by stratiﬁed sampling into two halves. One
half was used to ﬁt a logistic regression model, which was then used
to calculate out-of-sample predictive scores for the other half. This ran-
dom half-and-half split procedure was repeated a number of times
equal to three times the sample size of the training set; out-of-sample
predictive scores and the corresponding true outcomes were aggregat-
ed over all random splits and AUCs were estimated from these. Since
there are ﬁve training sets, ﬁve such AUC estimates were generated
for each panel, which were then averaged. Panel selection was carried
out by examining various summaries of protein performance, and also
direct examination of the panels with the best AUC estimates. To com-
pute the ﬁnal AUC estimates of the selected panels, each test set was
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set; the resulting out-of-sample predictive scores and true outcomes
aggregated over all ﬁve test sets, forming the ﬁnal set from which
AUCs were estimated.
2.7. Data Submission
Data submissions conformed to published guidelines (Martinez-
Bartolome et al., 2013). LC–MS data are accessible at http://
proteomecentral.proteomexchange.org, identiﬁer PXD000517. MRM-
MS data are available at http://www.peptideatlas.org/passel/, identiﬁer
PASS00336 for the MRM-MS assay qualiﬁcation data on the discovery
samples, and PASS00338, and PASS00339 part 1 and part 2 for the ver-
iﬁcation sample data. Expression data are accessible at http://enews.
patricbrc.org/niaid-clinical-proteomics/, identiﬁer ZFY for the discovery
data, ZBK for the MRM-MS qualiﬁcation data, and ZFX and ZGO for the
veriﬁcation phase data.
3. Results
3.1. Serum Protein Changes Associated With TB
In the discovery phase we compared HIV− TB cases (n= 19) toMtb
uninfected and LTBI controls (n=20; Fig. 1 and Table 1). As anticipated,
these two groups differed in most of their demographic and clinical
variables. They were compared in order to capture the full spectrum
of TB associated changes, and to generate a complete picture of the
host biology affected by the disease. One hundred sixty ﬁve proteins
were signiﬁcantly differentially expressed in HIV− TB compared to
Mtb uninfected and LTBI controls (Fig. 2). Since only two proteins, FTL
and SHBG, showed a different pattern of expression betweenMtb unin-
fected and LTBI controls, these groupswere combined for greater statis-
tical power. The differentially expressed proteins identiﬁed segregated
into a small number of biological processes, such as the immune
response, lipid transport and regulation, and tissue development and
repair (Fig. 2). Approximately a third of the differentially expressed pro-
teins represented different aspects of the immune response such as the
movement of phagocytes, neutrophils, and granulocytes, inﬂammation,
stress response, and the innate immune response. Most of the proteins
associated with the immune response were up regulated in the TB sub-
jects, consistent with a host response to an active infection. In contrast,
most proteins associated with lipid processing were down regulated.
Proteins involved in tissue development and repair were up or down
regulated, and associated with wound healing, mechanical damage to
lung tissue, and extracellular matrix protein biology.Fig. 2. Differentially expressed proteins in sera of HIV− subjects with active tuberculosis (TB) r
ferentially expressed proteins are indicated by dots and categorized by functional groups. Inten
scale (y-axis). Mean and standard deviation of the expression ratio of TB versus controls are shAfter excluding proteins that were components of the acute phase
response or had been repeatedly observed to be differentially expressed
in other non-TB diseases (Ray et al., 2014), 87 host proteinswere select-
ed for inclusion into a multiplex MRM-MS assay for the veriﬁcation
phase. These included 18 proteins derived from the discovery phase
of studies assessing protein biomarkers in more advanced Brazilian
HIV− and South African HIV+ TB patients. The additional proteins
complemented the small US sample number of advanced HIV− and
the lack of HIV+ TB subjects in our discovery phase. The studies were
not combined because they had different designs, and the Brazilian
and South African studies were not completed at the time of data anal-
ysis. Of note, the majority of proteins selected for the veriﬁcation phase
overlapped between the various sites. Two Mtb culture ﬁltrate proteins
(Malate synthase andMPT51)were included because theywere known
to induce a humoral immune response in our HIV− and HIV+ TB groups
(Achkar et al., 2010; Yu et al., 2012) but noMtb proteins were detected
in any of the serum samples in the discovery phase.3.2. Candidate Serum Protein Biomarkers for TB
An independent set of serum samples were used in the veriﬁcation
phase to validate the discovery data, and determine the clinically rele-
vant biomarkers that could distinguish TB from ORD. After exclusion
of samples due to remaining unknown HIV status or technical issues,
these samples were comprised of HIV− and HIV+ subjects with either
TB (n = 28), no Mtb infection or LTBI (n = 73), or subjects suspected
of having TB but ultimately diagnosed with ORD (n = 45; Fig. 1 and
Table 1). Due to our hypothesis that the host protein expression in TB
will differ according to HIV status, the HIV− and HIV+ groups were
analyzed separately. The differential expression of the host proteins
measured by LC–MS in the ﬁrst sample set was comparable to their cor-
responding expression when quantiﬁed by MRM-MS in the second
sample set though themagnitude of the changes observedwere greater
in the MRM-MS tested sample set, consistent with the increased sensi-
tivity of the MRM-MS assay (Supp. Table 1).
As anticipated, the comparison of TB to ORD resulted in different
expression patterns than the comparison to LTBI (Fig. 3). The presence
of an HIV co-infection reduced the overall magnitude of the host re-
sponse, and induced other more subtle changes. The MRM-MS data
was then split into training and test sets to derive biomarker panels
able to distinguish TB from ORD (Fig. 1). In the HIV− and HIV+ groups
the best single markers had a classiﬁcation performance (AUC) of up
to 0.80 and 0.77, respectively. When used in combinations, a subset of
10 candidates for the HIV− and 8 for the HIV+ groups, distinguished
TB from ORD with excellent accuracy (AUC 0.96 and 0.95, respectively;elative to controls (M. tuberculosis uninfected and latentM. tuberculosis infection). The dif-
sity values per proteinwere normalized and the ratios derived are displayed in logarithmic
own.
Fig. 3.Differential expression of candidate TB biomarkers in sera. Protein expression ratios expressed as fold change in subjectswith active tuberculosis (TB) relative to uninfected controls
(NI) and latentM. tuberculosis infection (LI), or relative to subjects with other respiratory diseases (ORD), in HIV+ or HIV− infected groups. The numerators and denominators per com-
parison and the color scale are indicated. The ratio range was from 0.2 to 6.6. The HIV− and HIV+ panel members are indicated by * and † respectively.
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and larger studies are needed to establish accurate conﬁdence intervals.
The composition of the panels differed according to HIV status but two
of the candidates (CD14 and SEPP1) were present in both groups. Of
note, we did neither observe signiﬁcant differences in the biomarker
protein expression between smear-positive and smear-negative TB,
culture-positive and culture-negative TB, nor pulmonary and extra-
pulmonary TB, although these subgroup comparisons were limited by
very small sample size. Furthermore, our spectrum of ORD included
5 nontuberculous mycobacterial (NTM) diseases in HIV+ patients
(Table 1). Comparison of those 5 HIV+ NTM to the 10 HIV+ TB patients
showed that 5/8 candidate proteins (SEPP1, PGLYRP2, VASN, CPN2,
TAGLN2) were signiﬁcantly differentially expressed between these
two groups. Thus, there appears to be both a partial overlap as well as
a TB speciﬁc signature of our protein biomarker candidates. Larger stud-
ies are needed to determine the accuracy of certain panel proteins to
distinguish between TB and NTM disease.
4. Discussion
Our data demonstrate that the physiological changes associated
with TB, including the effects of HIV co-infection, are reﬂected by the
human host protein patterns in blood. Small panels of proteins could
accurately distinguish TB from LTBI and ORD in HIV− and HIV+ individ-
uals. Particularly relevant for clinical practice was that our biomarker
signature was detectable in both smear-positive and smear-negative
TB, including culture-negative TB, indicating a high sensitivity for early
as well as more advanced TB. Furthermore, the high speciﬁcity was
estimated based on TB suspects ultimately diagnosed with an ORD,
the clinically relevant comparator group. In addition, following the ex-
pression levels of host proteins during antituberculous therapy might
allow rapid assessment of the treatment response, and offer advantages
over the currently used culture method. Although these results require
validation in larger studies, our data hold promise that the detection of
host protein changes could provide the basis for adjunctive rapid TB
diagnostics, either by immunoassay or by using portable MS devices
that are becoming more available (Wiley et al., 2013; Hendricks et al.,
2014; Creamer et al., 2014).Table 2
Composition of the host protein biomarker panels distinguishing active tuberculosis from
other respiratory diseases.
Functional category HIV− TB panel HIV+ TB panel
Immune response CD14, SEPP1, SELL CD14, SEPP1, PGLYRP2
Tissue development
& repair
TNXB, LUM, PEPD,
QSOX1, COMP
PFN1, VASNa
Lipid metabolism APOC1 –
Other GP1BA CPN2, TAGLN2, IGFBP6a
a Proteins introduced from discovery phase of Brazilian and South African samples
(unpublished data).The panel proteins were derived from the most prominently ob-
served TB related host processes— the immune response, tissue repair,
and lipid metabolism. As combinations of antituberculous and host-
modulating therapies hold promise to improve bacterial clearance
(Gonzalez-Juarrero, 2012; Maiga et al., 2012; Martins, 2011), the host
protein changes described in this work could also offer insights into
which host/pathogen combination therapies may be promising. Soluble
CD14 (sCD14) and SEPP1 were present in the TB panels for HIV+ and
HIV− subjects. CD14 is a marker of pulmonary inﬂammation (Anas
et al., 2010). Consistent with our ﬁndings, membrane and soluble
CD14 become up regulated in TB (Druszczynska et al., 2013; Lawn
et al., 2000; Hoheisel et al., 1995). Other infections or respiratory dis-
eases also induce elevated sCD14, albeit usually at lower levels than
TB (Hoheisel et al., 1995; Lawn et al., 2000), also consistent with our
observations. SEPP1, which was down regulated in TB, is involved in
selenium transport and homeostasis. SEPP1 deﬁcient mice experience
greater morbidity and mortality in Trypanosoma infection (Burk and
Hill, 2009), apparently due to increased tissue injury associated with
enhanced production of reactive oxygen species (Bosschaerts et al.,
2008).
Among the other candidate proteins in the HIV− group, GP1BA is
involved in pulmonary inﬂammation (McNicol and Israels, 2008), and
both SELL and LUM are involved in leukocyte homing and inﬁltration
(Wedepohl et al., 2012; Lee et al., 2009). TNXB is commonly expressed
by myoﬁbroblasts located in and underneath newly formed epithelia
at the foci of recent lung lesions (Kaarteenaho-Wiik et al., 2000; Paakko
et al., 2000) where it promotes the disassembly of focal adhesions
and stimulates cell migration (Murphy-Ullrich et al., 1991; Petit and
Thiery, 2000). Fibrogenesis and matrix turnover are enhanced in TB
compared to other granuloma-generating diseases such as sarcoidosis
(Kaarteenaho-Wiik et al., 2007), which underscores the physiological
relevance of TNXB. The other three biomarker candidates involved inFig. 4. Discrimination of active tuberculosis from other respiratory diseases. Area under
the receiver operating curve (AUC) is shown for the biomarker panels in HIV− (A) and
HIV+ (B) subjects.
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genesis and remodeling of the extracellular matrix (Haleem-Smith
et al., 2012; Ilani et al., 2013; Kitchener and Grunden, 2012).
APOC1 has known roles in lipid transport and regulation (Jong et al.,
1999). It has also been shown to enhance lipopolysaccharide (LPS)-
induced inﬂammatory responses which depend on CD14/Toll-like
receptor 4 signaling (Berbee et al., 2010). Mtb infection induces upreg-
ulation of host genes involved in lipid metabolism (Kim et al., 2010;
Russell et al., 2010; Singh et al., 2012). Host lipid metabolism is also
affected systemically by the acute phase response. For example, high
density lipoprotein (HDL) levels become reduced and their composition
is also altered (Khovidhunkit et al., 2004; Garcia-Gomez et al., 2014).
Thus, our observed changes associated with lipid metabolism could
reﬂect the sum of these metabolic adjustments. Also consistent with
our observations, changes in lipid metabolism have been observed in
sera and sputa of TB subjects by metabolomics (du Preez and Loots,
2013; Weiner et al., 2012).
In the HIV+ group, the panel proteins reﬂected predominantly
immune response and tissue repair functions. The down regulation of
VASN is associated with arterial injury and contribution to neointimal
formation (Ikeda et al., 2004). PFN1, which was also down regulated,
contributes to wound healing by increasing cellular motility (Bae
et al., 2010). CPN2 is a negative regulator of multiple inﬂammatory
response proteins (Skidgel and Erdos, 2007). PGLYRP2, a protein associ-
atedwith innate immune responses (Lee et al., 2012), was also reduced.
The remaining two proteins in the HIV+ panel, IGFBP6 and TAGLN2
have unknown roles in infectious diseases. Of note, ligands of IGFBP6
are reduced in sera and pleural ﬂuids of subjects with tuberculous and
non-tuberculous pleuritis (Le Bouc et al., 1997).
The different compositions of the protein biomarker panels for HIV−
and HIV+ subjects is consistent with the effect of HIV co-infection on TB
pathogenesis and disease presentation (reviewed in (Achkar and Jenny-
Avital, 2011)). HIV+ individuals commonly have a diminished inﬂam-
matory response to TB (Achkar and Jenny-Avital, 2011). Consistent
with our data indicating less tissue damage and repair in comparison
to the HIV− TB group, TB in HIV+ individuals is often associated with
granuloma impairment resulting in a lack of pulmonary cavity forma-
tion (Achkar and Jenny-Avital, 2011). Although most of the panel pro-
teins had known functions relevant to the host response to TB, their
up or down regulation could be induced by conditions other than TB.
The panel speciﬁcity thus resided in using combinations of biomarkers
that represented multiple TB-associated host responses. This suggests
that a holistic consideration of the host response would be required to
design a TB-speciﬁc test if based on host proteins, which is consistent
with the ﬁndings in other host biomarker studies of TB as well as
other complex and chronic diseases (Lesho et al., 2011; Maertzdorf
et al., 2011; Lu et al., 2011; Berry et al., 2010; Anderson et al., 2014;
Kaforou et al., 2013; De Groote et al., 2013; du Preez and Loots, 2013;
Nahid et al., 2014; Weiner et al., 2012; Li et al., 2013).
Due to the urgent need for additional tools to rapidly diagnose
TB, drug resistance, and treatment response, TB biomarker research
remains an active ﬁeld that utilizes multiple approaches (reviewed in
(Walzl et al., 2015). To identify potentially clinically relevant TB bio-
markers and limit bias of diagnostic accuracy, we analyzed samples
from consecutively enrolled TB suspects and compared TB cases to
patients with respiratory diseases other than TB in our veriﬁcation
phase. Using a broadly comparable study design, Xu et al. compared
TB cases to patients with either pneumonia or lung cancer, albeit with
the limitations that i) these patients appeared to be selected rather
than consecutively enrolled TB suspect, and ii) no information on HIV
testing results was provided (Xu et al., 2015). Samples were analyzed
by iTRAQ, a labeling technique that attaches mass tags to the sample
peptides prior to MS analysis. The differences between iTRAQ and the
label free quantitative MS we used have been described (Bantscheff
et al., 2012; Patel et al., 2009), and center around the greater resolution
and dynamic range of the label free method, as also indicated by thegreater number of differentially expressed proteins identiﬁed in our
work. In addition, Xu et al. pooled samples for discovery and did bio-
marker veriﬁcation by ELISA. We used label-free MS for both discovery
and veriﬁcation, did not pool samples, and also employed statistical
methods speciﬁcally designed to reduce overﬁtting. Despite these dif-
ferences, 24 of 34 differentially expressed proteins reported by Xu
et al. were also detected in the HIV-groups of our study, and 17 of
these were also differentially expressed in the same direction although
not always with the same magnitude. The differences in the ﬁnal panel
biomarkers we report are probably a result of the different analytical
and statisticalmethods used. An earlierwork from the samegroup com-
pared sera from TB patients to healthy controls, and identiﬁed 4 candi-
date biomarkers that were not differentially expressed in their latter
work, although 2 of them (APOCII, CD5L) were differentially expressed
in our study (Xu et al., 2014). Another proteomics study of comparable
design used label free MS to compare TB cases to a mixture of patients
with non-respiratory medical problems (Song et al., 2014). Of the 21
proteins reported to be differentially expressed in that study, 18 (86%)
were also detected in our work. Most of those proteins were associated
with inﬂammatory responses consistent with a host response to an ac-
tive infection. However, since TB patients were compared to patients
with non-respiratorymedical problems, the speciﬁcity of these proteins
for TB in comparison to ORD could not be readily assessed.
Of the earlier studies, Zhang et al. compared TB to healthy controls
and ORD, and identiﬁed ORM1 as a candidate biomarker (Zhang et al.,
2012). Agranoff et al. compared TB subjects to ORD and inﬂammatory
diseases, and concluded that serum amyloid (SAA1), C reactive protein
(CRP), and transthyretin (TTR) were the most useful candidate protein
biomarkers along with neopterin, a metabolite (Agranoff et al., 2006).
Liu et al. (BMC Infect. Dis 2013; 13:506) compared TB cases to healthy
controls and ORD, and identiﬁed a degradation product of ﬁbrinogen
A (FGA) as a candidate biomarker (Liu et al., 2013). ORM1, SAA1, CRP,
and FGA were also found upregulated by TB in our study. However,
since they were components of the non-speciﬁc acute phase response
or coagulation pathway, we did not pursue them further as candidate
biomarkers. TTR was removed by the abundant protein depletion
column we used. The results of proteomic studies that did not provide
candidate peptide or protein biomarker identiﬁcations could not be
readily compared (Deng et al., 2011; Liu et al., 2010, 2015).
Targeted proteomics studies that used aptamer-based enrichment
have been done to identify biomarkers associated with response to
treatment (De Groote et al., 2013; Nahid et al., 2014). Although these
studies a priori targeted a different set of proteins than our study, and
had a different objective, many of the candidate biomarkers identiﬁed
were associated with the main biologies described in our study —
immune response and tissue repair, which supports that these are im-
portant elements of the host response to TB. Transcriptional proﬁling
studies of blood cell RNA were also able to identify signatures speciﬁc
to TB through analysis of changes related to immune cell activation,
although comparatively large panels of 44–86 biomarker genes were
necessary to distinguish TB from other diseases (Anderson et al., 2014;
Kaforou et al., 2013; Berry et al., 2010).
Our study was limited to enrollment at sites in New York City.
Nevertheless, our subjects revealed a broad spectrum in demographics,
particularly race and country of origin. This is not surprising, as TB in the
US, and particularly in New York City, is a disease predominantly diag-
nosed in foreign-born individuals who typically are infected during
childhood with the Mtb strains prevalent in their country of origin
(New York City Department of Health and Mental Hygiene, 2013;
CDC, 2013). Our subjects originated from various countries of North,
Central and South America, Africa and Asia. We therefore believe that
our results are neither restricted to one part of the world nor to one
particular Mtb strain. Another relevant limitation was the small sample
size. Yet, we were able to demonstrate statistically signiﬁcant differ-
ences between TB cases and controls, as well as highly reproducible
data when comparing the discovery to the veriﬁcation protein
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studies using larger sample sizes from both HIV− and HIV+ subjects
from various regions are warranted to validate the robustness of our
panel compositions as well as identify any potential regional variations.
In summary, our data are to a large part consistent with the ﬁeld's
data, while, through the use of label-free MS, we expanded the number
of host proteins changing as a result of TB in comparison to ORD that
mimic the clinical presentation of TB. Furthermore, in contrast to prior
studies, we have analyzed samples in both immune competent and im-
mune compromised hosts, and have identiﬁed moderately sized panels
of host protein biomarkers with diagnostic potential in both HIV nega-
tive aswell as HIV-associated TB.We conclude that our data hold prom-
ise that the detection of host protein changes could provide the basis for
adjunctive rapid TB diagnostics. Larger studies from various geographic
regions are warranted to validate the robustness and potential clinical
value of our identiﬁed TB biomarker panels in relevant populations.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.07.039.
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